Entrada Therapeutics Stock Market Value
| TRDA Stock | USD 19.37 0.33 1.73% |
| Symbol | Entrada |
Entrada Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Entrada Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Entrada Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Entrada Therapeutics.
| 10/27/2024 |
| 11/26/2024 |
If you would invest 0.00 in Entrada Therapeutics on October 27, 2024 and sell it all today you would earn a total of 0.00 from holding Entrada Therapeutics or generate 0.0% return on investment in Entrada Therapeutics over 30 days. Entrada Therapeutics is related to or competes with Molecular Partners, Pmv Pharmaceuticals, Monte Rosa, Vigil Neuroscience, Third Harmonic, Cullinan Oncology, and Edgewise Therapeutics. Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle therapeutics for the treatment of... More
Entrada Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Entrada Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Entrada Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.11 | |||
| Information Ratio | 0.0426 | |||
| Maximum Drawdown | 18.81 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 6.14 |
Entrada Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entrada Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Entrada Therapeutics' standard deviation. In reality, there are many statistical measures that can use Entrada Therapeutics historical prices to predict the future Entrada Therapeutics' volatility.| Risk Adjusted Performance | 0.07 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0451 | |||
| Treynor Ratio | 0.1127 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entrada Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entrada Therapeutics Backtested Returns
Entrada Therapeutics appears to be not too volatile, given 3 months investment horizon. Entrada Therapeutics secures Sharpe Ratio (or Efficiency) of 0.089, which denotes the company had a 0.089% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Entrada Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Entrada Therapeutics' Mean Deviation of 2.37, downside deviation of 3.11, and Coefficient Of Variation of 1226.1 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Entrada Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 2.3, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entrada Therapeutics will likely underperform. Please check Entrada Therapeutics' value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Entrada Therapeutics' price patterns will revert.
Auto-correlation | -0.33 |
Poor reverse predictability
Entrada Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Entrada Therapeutics time series from 27th of October 2024 to 11th of November 2024 and 11th of November 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Entrada Therapeutics price movement. The serial correlation of -0.33 indicates that nearly 33.0% of current Entrada Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.33 | |
| Spearman Rank Test | -0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.78 |
Entrada Therapeutics lagged returns against current returns
Autocorrelation, which is Entrada Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Entrada Therapeutics' stock expected returns. We can calculate the autocorrelation of Entrada Therapeutics returns to help us make a trade decision. For example, suppose you find that Entrada Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Entrada Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Entrada Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Entrada Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Entrada Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Entrada Therapeutics Lagged Returns
When evaluating Entrada Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Entrada Therapeutics stock have on its future price. Entrada Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Entrada Therapeutics autocorrelation shows the relationship between Entrada Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Entrada Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out Entrada Therapeutics Correlation, Entrada Therapeutics Volatility and Entrada Therapeutics Alpha and Beta module to complement your research on Entrada Therapeutics. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Entrada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.